Glasdegib Renal Impairment Study

Renal Impairment Clinical Trial

Official title:

A PHASE 1, OPEN-LABEL, SINGLE DOSE, PARALLEL GROUP STUDY TO EVALUATE THE PHARMACOKINETICS OF GLASDEGIB (PF-04449913) IN SUBJECTS WITH IMPAIRED RENAL FUNCTION

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03596567
• Other study ID #: B1371017
• Status: Completed
• Phase: Phase 1
• Start date: May 17, 2018
• Est. completion date: September 19, 2018

Study information

• Verified date: August 2019
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this study is to administer single dose (100 mg) glasdegib tablet to subjects with normal, moderate and severe renal impairment and estimate the effect, if any, of this renal impairment on glasdegib pharmacokinetics.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: September 19, 2018
• Est. primary completion date: August 28, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Healthy female subjects of non child bearing potential and/or male subjects who, at the time of screening, are between the ages of 18 and 75 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG or clinical laboratory tests.

2. Female subjects of nonchildbearing potential must meet at least 1 of the following criteria:

1. Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; with a serum follicle stimulating hormone (FSH) level confirming the postmenopausal state;

2. Have undergone a documented hysterectomy and/or bilateral oophorectomy;

3. Have medically confirmed ovarian failure. All other female subjects (including females with tubal ligations) are considered to be of childbearing potential.

3. Body mass index (BMI) of 17.5 to 40 kg/m2; and a total body weight >50 kg (110 lb).

4. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study.

5. Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

Subjects with Normal Renal Function will Need to Meet the Following Criteria in addition -

1. Normal renal function, eGFR=>90 mL/min, based on the MDRD equation.

2. Matched for age (+/-10years) weight +/-15kg, and gender to subjects in the impaired renal function groups

Subjects with Impaired Renal Function will Need to Meet the Following Criteria in Addition to Those Above

1. Good general health commensurate with the population with chronic kidney disease (renal impairment). 'Health' is defined as no clinically relevant abnormalities (with the exception of hypertension, diabetes mellitus, hyperparathyroidism, ischemic heart disease, etc. as long as, in the opinion of the investigator, the subject is medically stable, is on a stable drug regimen and can abide by the meals and dietary restrictions outlined in protocol identified by a detailed medical history, full physical examination, measurement of pulse rate and 12 lead ECG as well as clinical laboratory tests (except serum creatinine and eGFR).

2. Stable drug regimen defined as not starting a new drug or changing dosage within seven days or five half lives (whichever is longer) before dosing the study drug.

3. Any form of renal impairment except acute nephritic syndrome (subjects with history of previous nephritic syndrome but in remission can be included).

4. Meet one of the following eGFR criteria during the screening period based on the MDRD equation:

1. Moderate renal impairment: eGFR 30 mL/min and <60 mL/min, or

2. Severe renal impairment: eGFR <30 mL/min, but not requiring hemodialysis. For subjects in all groups, the values of serum creatinine obtained at the two screening visits should not be more than 20% different.

Exclusion Criteria:

-Any condition possibly affecting drug absorption (eg, gastrectomy, achlorhydria).

Renal allograft recipients

Urinary incontinence without catheterization.

Concurrent use of any of the following food or drugs known to inhibit CYP3A4 (consult the Sponsor if in doubt whether a food or a drug falls into any of the above categories) within 7 days or 5 half lives (whichever is longer) prior to the dose of glasdegib, until the completion of the last PK sample collection.

Concurrent use of any of the following food or drugs known to induce CYP3A4 (consult the Sponsor if in doubt whether a food or a drug falls into any of the above categories) within 12 days or 5 half lives (whichever is longer) prior to the first dose of trial medication until the completion of the last PK sample collection.

Pregnant female subjects; breastfeeding female subjects; fertile male subjects who are unwilling or unable to use two highly effective methods of contraception as outlined in this protocol for the duration of the study and for at least 90 days after the last dose of investigational product and, refrain from sperm donation for the duration of the Study and for at least 90 days after the last dose of investigational product.

Subjects with ANY of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:

• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level > upper limit of normal (ULN);

• Total bilirubin level 1.5 × ULN; subjects with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is not greater than 0.5 mg/dL.

For subjects with renal impairment, the following important additional criteria are:

Subjects with other clinically significant disease that may affect the safety of the subject or that may affect the pharmacokinetics of glasdegib (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). Subjects with any significant hepatic, cardiac, or pulmonary disease or subjects who are clinically nephrotic. Hypertension, diabetes mellitus, hyperparathyroidism, ischemic heart disease, etc is not cause for exclusion as long as the subject is medically stable and any drugs that are administered for these conditions are not expected to interfere with the pharmacokinetics of glasdegib.

Screening blood pressure =>180mm Hg (systolic) or>=110 mm Hg (diastolic), following at least 5 minutes of supine rest. If initial blood pressure (BP) is 180 mm Hg (systolic) or 110 mm Hg (diastolic), the BP should be repeated two more times and the average of the three BP values should be used to determine the subject's eligibility.

Screening supine 12 lead ECG demonstrating QTcF >470 msec or a QRS interval >120 msec. If initial QTcF exceeds 470 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTcF or QRS values should be used to determine the subject's eligibility.

Related Conditions & MeSH terms

• Renal Impairment
• Renal Insufficiency

Intervention

Drug:
• Glasdegib single 100 mg dose in normal healthy subjects
A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow -up.
• Glasdegib single 100 mg dose in moderate renal impairment subjects
A single dose of 100 mg glasdegib tablet will be administered to subjects with moderate renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
• Glasdegib single 100 mg dose in severe renal impairment subjects
A single dose of 100 mg glasdegib tablet will be administered to subjects with severe renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.

Locations

Country	Name	City	State
United States	University of Miami Division of Clinical Pharmacology	Miami	Florida
United States	University of Miami, Sylvester Comprehensive Cancer Center	Miami	Florida
United States	Prism Clinical Research LLC	Saint Paul	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Observed Plasma Concentration (Cmax)		6 days
Primary	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]	AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).	6 days
Secondary	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).	concomitant medication and adverse event monitoring.	34 days
Secondary	PR/ECGs	PR interval (msec),	34 days
Secondary	Hematology Lab Panel	Platelet count (10^3/mm^3)	34 days
Secondary	BUN /Chemistry Lab Panel	BUN (mg/dL)	34 days
Secondary	pH/Urinalysis Lab Panel	pH (no unit)	34 days
Secondary	Blood Pressure	Supine Systolic and Diastolic blood pressure (mm of Hg). Reported as Systolic/Diastolic	34 days
Secondary	Pulse Rate	Pulse Rate will be reported in beats per minute.	34 days
Secondary	ECGs	Heart Rate (beats per minute)	34 days
Secondary	Hemoglobin /Hematology Lab Panel	Hemoglobin (g/dL)	34 days
Secondary	Hematology Lab Panel	Hematocrit (%)	34 days
Secondary	Hematology Lab Panel	RBC Count (10^6/mm^3)	34 days
Secondary	Hematology Lab Panel	MCV (femto Liters)	34 days
Secondary	Hematology Lab Panel	MCH (pictograms/cell)	34 days
Secondary	Potassium/Chemistry Lab Panel	Potassium (Meq/L)	34 days
Secondary	AST/Chemistry Lab Panel	AST (U/L)	34 days
Secondary	Albumin/Chemistry Lab Panel	Albumin (g/dL)	34 days
Secondary	MCHC/Hematology Lab Panel	MCHC (10^3/mm^3)	34 days
Secondary	WBC count/Hematology Lab Panel	WBC count (10^3/mm^3),	34 days
Secondary	Total neutrophils/Hematology Lab Panel	Total neutrophils (Abs)(10^3/mm^3),	34 days
Secondary	Eosinophils/Hematology Lab Panel	Eosinophils (Abs)(10^3/mm^3	34 days
Secondary	Monocytes/Hematology Lab Panel	Monocytes (Abs)(10^3/mm^3)	34 days
Secondary	Basophils/Hematology Lab Panel	Basophils (Abs) (10^3/mm^3)	34 days
Secondary	Lymphocytes/Hematology Lab Panel	Lymphocytes (Abs) (10^3/mm^3)	34 days
Secondary	Total Protein/Chemistry Lab Panel	Total Protein (g/dL)	34 days
Secondary	ALT/Chemistry Lab Panel	ALT (U/L)	34 days
Secondary	Alkaline Phosphate/Chemistry Lab Panel	Alkaline Phosphate (U/L)	34 days
Secondary	Sodium/Chemistry Lab Panel	Sodium (Meq/L)	34 days
Secondary	Chloride/Chemistry Lab Panel	Chloride (Meq/L)	34 days
Secondary	Creatinine/Chemistry Lab Panel	Creatinine (mg/dL),	34 days
Secondary	Glucose/Chemistry Lab Panel	Glucose (mg/dL),	34 days
Secondary	Calcium/Chemistry Lab Panel	Calcium (mg/dL),	34 days
Secondary	Total Bilirubin/Chemistry Lab Panel	Total Bilirubin (mg/dL),	34 days
Secondary	Uric acid/Chemistry Lab Panel	Uric acid (mg/dL)	34 days
Secondary	Magnesium/Chemistry Lab Panel	Magnesium (mg/dL)	34 days
Secondary	QTc/ECGs	QTc interval (msec)	34 days
Secondary	QRS/ECGs	QRS interval (msec)	34 days
Secondary	Glucose/Urinalysis Lab Panel	Glucose (qual) (no unit)	34 days
Secondary	Protein/Urinalysis Lab Panel	Protein (qual) (no unit)	34 days
Secondary	Blood/Urinalysis Lab Panel	Blood (qual) (no units)	34 days
Secondary	Ketones/Urinalysis Lab Panel	Ketones (no units)	34 days
Secondary	Nitrites/Urinalysis Lab Panel	Nitrites (no units)	34 days
Secondary	Leukocyte /Urinalysis Lab Panel	Leukocyte esterase (no units)	34 days
Secondary	Urobilinogen/Urinalysis Lab Panel	Urobilinogen (no unit)	34 days
Secondary	Urine bilirubin/Urinalysis Lab Panel	Urine bilirubin (no unit)	34 days

External Links

•   To obtain contact information for a study center near you, click here.